{"id":"exviera","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Elevated bilirubin"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EXVIERA combines dasabuvir (NS5B inhibitor) with ombitasvir and paritaprevir (NS5A and NS3/4A inhibitors respectively) to target multiple sites of HCV replication. This multi-targeted approach achieves high cure rates across HCV genotypes with shorter treatment durations and improved tolerability compared to earlier interferon-based regimens.","oneSentence":"EXVIERA is a direct-acting antiviral (DAA) combination therapy that inhibits hepatitis C virus (HCV) NS5A and NS5B proteins to prevent viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:04.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, genotypes 1 and 4"}]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT02219490","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10-30","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":1596},{"nctId":"NCT02167945","phase":"PHASE3","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06-12","conditions":"Chronic Hepatitis C Virus (HCV) Infection Genotype 1","enrollment":615},{"nctId":"NCT02486406","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-28","conditions":"Chronic Hepatitis C Infection","enrollment":64},{"nctId":"NCT03201718","phase":"","title":"A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-17","conditions":"Hepatitis C Virus (HCV)","enrollment":505},{"nctId":"NCT03002818","phase":"","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus (HCV)","enrollment":41},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":"HCV Coinfection","enrollment":7},{"nctId":"NCT04047680","phase":"","title":"eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Hepatitis C, Renal Disease, Viral Hepatitis C","enrollment":441},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT03122132","phase":"","title":"Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks","status":"COMPLETED","sponsor":"Hepa C","startDate":"2017-02-20","conditions":"Hepatitis C Infection","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dasabuvir"],"phase":"marketed","status":"active","brandName":"EXVIERA","genericName":"EXVIERA","companyName":"HaEmek Medical Center, Israel","companyId":"haemek-medical-center-israel","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EXVIERA is a direct-acting antiviral (DAA) combination therapy that inhibits hepatitis C virus (HCV) NS5A and NS5B proteins to prevent viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1 and 4.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}